基胺辅助布普伦诺芬启动:一个试点案例系列
Lucinda A Grande1,2, Tom Hutch3,4, Keira Jack3
1Pioneer Family Practice, 5130 Corporate Ctr Ct SE, Lacey, Washington, 98503, USA. cgrande@pioneerfamilypractice.com.
Addiction science & clinical practice
|August 29, 2024
概括
舌下胺有效降低了阿片类药物戒断症状,使更多患者能够在门诊环境中开始服用布普伦诺芬治疗. 这种方法可能会降低对基本成治疗的障碍.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 临床研究 临床研究
背景情况:
- 阿片类药物使用障碍 (OUD) 治疗受到阿片类药物戒断的恐惧所阻碍.
- 由于担心自发性或布普伦诺芬沉性阿片类药物戒断 (BPOW),布普伦诺芬的开始往往会被推迟.
- 胺在治疗BPOW方面表现出潜力,但其在门诊环境中的使用需要小心剂量,以避免分离作用.
研究的目的:
- 探索低剂量,自给自取的舌下胺的疗效,以促进OUD的门诊患者的布普伦诺芬启动.
- 评估胺在缓解戒断症状中的作用,在从芬太尼或甲过渡到布普伦诺芬期间.
主要方法:
- 处方下舌胺 (16毫克每剂量,4-8剂量) 转换为布普伦诺芬的患者,他们担心BPOW或正在经历它.
- 每天或几乎每天监测患者,根据反应调整胺和布普伦诺芬剂量.
- 包括从非法芬太尼和甲过渡的患者.
主要成果:
- 37名患者被处方胺;16名 (43%) 完成了布普伦诺芬启动.
- 在那些尝试过胺的人中,67%成功启动了布普伦诺芬.
- 大多数患者报告戒断症状减少或消除,92%的过去12个完成者有30天的保留时间.
- 一个协议允许四名患者在四天内开始服用布普伦诺芬,并缓和戒断.
结论:
- 亚分离式胺促进了大多数尝试它的患者的门诊布普伦诺芬启动.
- 胺可以减少恐惧和降低对布普伦诺芬治疗的障碍.
- 需要进一步的研究来证实这些发现,并为各种环境开发标准化的协议.
相关概念视频
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
251
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
251
01:24Parenteral Anesthetics: Overview
111
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
111